Silexion Therapeutics Corp. has received a notice from the Nasdaq Stock Market LLC regarding a regulatory issue related to its stock listing. The Listing Qualifications Department informed Silexion that the closing bid price of its ordinary shares has been below the minimum $1.00 per share requirement for 30 consecutive business days, as per Nasdaq Listing Rule 5550(a)(2). This bid price deficiency could impact Silexion's continued listing on the Nasdaq Capital Market. While the letter does not immediately affect the trading of Silexion's ordinary shares or warrants, it will be considered by the Nasdaq hearings panel in deciding whether the company can remain listed. Silexion has until September 19, 2025, to meet compliance terms and achieve the required standards for listing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.